Hydroxychloroquine. Photo: George Frey/AFP via Getty Images

Editor’s note: The study referenced in this story has been retracted by the medical journal The Lancet due to questions on the veracity of its primary data sources. Read more here.

Coronavirus patients who took hydroxychloroquine or its related drug chloroquine were more likely to die or develop an irregular heart rhythm that can lead to sudden cardiac death, compared to those who did nothing, a retrospective review published in The Lancet shows.

Why it matters: Despite warnings from the Food and Drug Administration, President Trump has insisted the anti-malarial drug as a "game-changer" and admitted he has taken it as a preventative even though the drug is unproven.

The big picture: The medical journal's review consisted of 96,000 hospitalized patients diagnosed with the coronavirus in six continents, the largest analysis of medical records on the drug, between Dec. 20, 2019, and April 14, 2020.

  • About 15,000 of the 96,000 patients were treated with hydroxychloroquine or chloroquine alone, or combined with an antibiotic known as a macrolide.

The findings: Those given the drug alone had a 34% increased risk of dying and a 137% increased risk of heart arrhythmias.

  • Those who took the drug paired with an antibiotic had a 45% increased risk of death and a 411% risk of heart arrhythmias. This combination is one President Trump has been encouraging.

The mean age of patients was 54 years old and 53% were men.

  • Those excluded were those on mechanical ventilators or who received remdesivir, an antiviral drug made by Gilead Sciences.

The bottom line: The FDA has adamantly warned against taking hydroxychloroquine or chloroquine because of the risk of heart complications and unproven claims it prevents COVID-19 infections.

Go deeper: Stunned Fox News host reacts to Trump taking hydroxychloroquine

Go deeper

Updated 8 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 10 p.m. EST: 32,135,220 — Total deaths: 981,660 — Total recoveries: 22,149,441Map.
  2. U.S.: Total confirmed cases as of 10 p.m EST: 6,975,980 — Total deaths: 202,738 — Total recoveries: 2,710,183 — Total tests: 98,481,026Map.
  3. Politics: House Democrats prepare new $2.4 trillion coronavirus relief package.
  4. Health: Cases are surging again in 22 states — New York will conduct its own review of coronavirus vaccine.
  5. Business: America is closing out its strongest quarter of economic growth.
  6. Technology: 2020 tech solutions may be sapping our resolve to beat the pandemic.
  7. Sports: Pac-12 will play this fall despite ongoing pandemic — Here's what college basketball will look like this season.
  8. Science: Global coronavirus vaccine initiative launches without U.S. or China — During COVID-19 shutdown, a common sparrow changed its song.

The apocalypse scenario

Illustration: Aïda Amer/Axios

Democratic lawyers are preparing to challenge any effort by President Trump to swap electors chosen by voters with electors selected by Republican-controlled legislatures. One state of particular concern: Pennsylvania, where the GOP controls the state house.

Why it matters: Trump's refusal to commit to a peaceful transfer of power, together with a widely circulated article in The Atlantic about how bad the worst-case scenarios could get, is drawing new attention to the brutal fights that could jeopardize a final outcome.

Federal judge rules Trump administration can't end census early

Census workers outside Lincoln Center in New York. Photo: Noam Galai/Getty Images

A federal judge ruled late Thursday that the Trump administration could not end the 2020 census a month early.

Why it matters: The decision states that an early end — on Sept. 30, instead of Oct. 31 — would likely produce inaccuracies and thus impact political representation and government funding around the country.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!